Recently, a new phase I clinical trial has been initiated to explore the safety and anticancer efficacy profiles of [212Pb]Pb‐DOTAM‐GRPR1 in BC patients with tumours expressing GRPR at various levels, as well as other types of cancer (NCT05283330). Here, GRPR is linked to neoplasm.